EW — Edwards Lifesciences Corp

Edwards Lifesciences Corp (EW) is a medical devices company listed on NYSE. It is led by Bernard J. Zovighian, based in One Edwards Way, Irvine, CA, United States, 92614, with about 16,000 employees. Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Latest reported EW revenue for 2025-09-30 was $1.55B. Net income was $291.1M. Revenue was up 1.4% from 2025-06-30 to 2025-09-30. EW currently screens at market cap $49.91B and trailing P/E 46.9.

Use this EW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EW SEC filings page. Lician reads the product cache first so this HTML stays unique to Edwards Lifesciences Corp even when a live quote feed is slow.